UBRELVY 50 mg/1

UBRELVY 50 mg is a medication used for the acute treatment of migraines. It contains ubrogepant, a calcitonin gene-related peptide (CGRP) antagonist. This oral tablet is designed to provide relief from migraine headaches.

UBRELVY 50 mg is primarily used for the acute treatment of migraines in adults. It works by blocking the activity of CGRP, a molecule involved in migraine attacks. This medication is intended for use when migraine symptoms begin, helping to alleviate pain and associated symptoms. Ubrogepant is not intended for preventive use or for the treatment of other types of headaches.

Common effects of Ubrevly 50 mg may include nausea, somnolence, and dry mouth. Some users may experience fatigue or dizziness. These effects are generally mild and temporary. If any severe or persistent effects occur, it is important to consult a healthcare professional.

UBRELVY 50 mg should be used with caution in individuals with liver impairment. It is important to follow the prescribed dosage and not exceed the recommended amount. This medication should not be used for the prevention of migraines or for the treatment of other types of headaches. Always consult a healthcare professional before starting any new medication.

UBRELVY 50 mg may interact with other medications, including strong CYP3A4 inducers and inhibitors. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol should be avoided while using this medication, as it may increase the risk of side effects.